borderline significantP = .06
18 Patients treated with atorvastatin showed a borderline significant lower activity index score compared with the placebo group (132.1 vs 157.6, P = .06) at the end of the study period, but when adjusting for disease duration, atorvastatin treatment was associated with a significant decreased disease activity ( P = .02).